Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program
Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027
SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022.
“We are excited to advance our Kv7 program forward with ETX-123 as the lead candidate,” said Andrew Levin, M.D., Ph.D., Executive Chairman of Eliem Therapeutics. “Our Kv7 program utilizes a proven mechanism of action which we believe has the potential to improve the lives of patients suffering from a variety of CNS disorders. We look forward to presenting preclinical data at the 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets being held later this month. With a strong balance sheet funding operations into 2027, we are in an optimal position to execute on ETX-123 and the Kv7 program.”
- Announced Corporate Reorganization and Pipeline Reprioritization to Focus on Advancing High Potential Kv7 Program: In February, the Company’s Board of Directors determined that it is in the best interests of the Company and its stockholders to reprioritize Eliem’s pipeline to focus on its high potential preclinical Kv7.2/3 program (“Kv7 Program”) and the development of its lead Kv7.2/3 candidate, ETX-123. The Company paused all further development of ETX-155, a novel GABAA receptor positive allosteric modulator neuroactive steroid (“GABAA PAM”) that is Phase 2-ready for major depressive disorder (MDD), with the potential to also pursue development in epilepsy. As part of this reprioritization, the Company is retaining its core R&D team under the continued leadership of Dr. Valerie Morisset, EVP R&D and Chief Scientific Officer, to carry on driving forward the Kv7 Program and exploring other pipeline opportunities, and will reduce its workforce by approximately 55% in the first half of 2023.
- Appointed Andrew Levin as Executive Chairman: Following the corporate reorganization and departure of Bob Azelby, Eliem’s former President and Chief Executive Officer, Andrew Levin, current Chairman of the Board, was appointed as Executive Chairman overseeing the day-to-day operations of the Company.
- Cash Runway Extended into 2027: As a result of the corporate reorganization and pipeline reprioritization, the Company’s current cash, cash equivalents and marketable securities is expected to fund operations into 2027.
Program Updates and Anticipated Key Milestones
- The Company has initiated the scaling up synthesis of the lead Kv7 candidate, ETX-123, to enable the initiation of investigational new drug (IND)-enabling safety studies, with Phase 1 studies planned to initiate in the first half of 2024.
- The Company’s novel Kv7 compounds, including additional pre-candidates, have demonstrated high potency and differentiated selectivity in electrophysiology assays, and in vivo anticonvulsant activity in the maximal electroshock seizure (MES) rat model.
- Initial ETX-123 preclinical data will be presented at the 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets being held March 27-28, 2023 at the Wellcome Genome Campus in Cambridge, UK.
Fourth Quarter and Year-End 2022 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities were $123.6 million as of December 31, 2022, compared to $161.4 million as of December 31, 2021.
- Research and Development (R&D) expenses: R&D expenses were $4.9 million for the three months ended December 31, 2022, and $26.2 million for the full year 2022, compared to $6.9 million and $23.3 million for comparable periods in 2021, respectively.
- General and Administrative (G&A) expenses: G&A expenses were $4.6 million for the three months ended December 31, 2022, and $18.9 million for the full year 2022, compared to $3.8 million and $12.4 million for comparable periods in 2021, respectively.
- Net loss: Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022, compared to $10.5 million and $47.5 million for comparable periods in 2021, respectively.
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical and therapeutic potential of ETX-123; the progression of the Kv7.2/3 and next-generation anxiolytic preclinical programs, including the initiation of IND-enabling safety studies and planned initiation of Phase 1 studies in the first half of 2024; the exploration of future pipeline opportunities; Eliem’s reorganization and pipeline reprioritization, and the anticipated results thereof; the expectation that Eliem’s current cash, cash equivalents and marketable securities will fund operations through 2027; future data presentations; and Eliem’s commitment to developing therapies targeting debilitating disorders. Words such as “excited,” “advance,” “look forward,” “believe,” “potential,” “will,” “on track,” “expects,” “opportunities,” “planned,” “runway,” “initiate,” “anticipated,” “milestones,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Eliem's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the clinical, therapeutic and commercial value of ETX-123 and Eliem’s other preclinical programs; the availability of data at the expected times; Eliem's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Eliem's preclinical and clinical development activities; the sufficiency of Eliem's capital and other resources; risks and uncertainties related to regulatory application, review and approval processes and Eliem's compliance with applicable legal and regulatory requirements; market competition; changes in economic and business conditions; impacts on Eliem’s business due to external events, including health pandemics or other contagious outbreaks, such as the current COVID-19 pandemic; and other factors discussed under the caption "Risk Factors" in Eliem's Annual Report on Form 10-K for the year ended December 31, 2022. This filing, when available, is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Eliem expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Eliem's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
|Eliem Therapeutics, Inc.|
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|As of December 31,|
|Cash and cash equivalents||$||43,585||$||46,922|
|Short-term marketable securities||79,981||89,558|
|Prepaid expenses and other current assets||10,827||11,772|
|Total current assets||$||134,393||$||148,252|
|Operating lease right-of-use assets||471||—|
|Long-term marketable securities||—||24,919|
|Other long-term assets||128||70|
|Liabilities and stockholders’ equity|
|Operating lease liabilities||300||—|
|Total current liabilities||$||6,097||$||6,031|
|Other long-term liabilities||—||7|
|Operating lease liabilities, net of current portion||180||—|
|Commitments and contingencies|
|Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 26,567,681 shares issued and outstanding at December 31, 2022 and December 31, 2021||3||3|
|Additional paid-in capital||249,930||242,939|
|Accumulated other comprehensive loss||(358||)||(123||)|
|Total stockholders’ equity||$||128,715||$||167,203|
|Total liabilities and stockholders’ equity||$||134,992||$||173,241|
|Eliem Therapeutics, Inc.|
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
|Three Months Ended December 31,||Year Ended December 31,|
|Research and development||$||4,927||$||6,879||$||26,214||$||23,322|
|General and administrative||4,627||3,824||18,921||12,350|
|Total operating expenses||9,554||10,703||45,135||35,672|
|Loss from operations||(9,554||)||(10,703||)||(45,135||)||(35,672||)|
|Other income (expense):|
|Change in fair value of redeemable convertible preferred stock tranche liability||—||—||—||(11,718||)|
|Foreign currency gain (loss)||1,032||98||(1,484||)||(170||)|
|Interest income, net||760||60||1,375||80|
|Total other income (expense)||1,792||158||(109||)||(11,808||)|
|Accretion of redeemable convertible preferred stock to redemption value and cumulative preferred stock dividends||—||—||—||(4,548||)|
|Net loss attributable to common stockholders||$||(7,762||)||$||(10,545||)||$||(45,244||)||$||(52,028||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.29||)||$||(0.40||)||$||(1.72||)||$||(4.24||)|
|Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted||26,372,935||26,225,842||26,311,554||12,260,551|